Fiasp (fast-acting insulin aspart) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 7 Diseases   12 Trials   12 Trials   856 News 


«123456789»
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    New P3 trial, Combination therapy:  Afrezza (clinicaltrials.gov) -  Jul 22, 2021   
    P3,  N=264, Not yet recruiting, 
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, Apidra (insulin glulisine) / Sanofi, BioChaperone lispro (ultra fast-acting insulin analog) / Adocia
    Clinical, Review, Journal:  The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications. (Pubmed Central) -  Jun 26, 2021   
    Insulins, lispro, aspart and glulisine all achieved an earlier onset of action, greater peak effect and shorter duration of action resulting in lower PPG levels and a reduced risk of late postprandial hypoglycaemia...Recent reformulations of aspart and lispro have generated a second generation of more rapid-acting insulin analogue candidates, including fast-acting aspart (faster aspart), ultra-rapid lispro and BioChaperone Lispro...Phase 1 trials for BioChaperone lispro are equally encouraging with Phase 3 trials yet to be initiated. Comparative analysis of the clinical and pharmacological evidence for these new prandial insulin candidates in the treatment of type 1 and type 2 diabetes, is the main focus of this review.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk
    Journal:  Are newer insulin analogues better for people with Type 1 diabetes? (Pubmed Central) -  Jun 8, 2021   
    In the present review we discuss the currently available insulin analogues and the challenges of achieving glucose control using current analogues in those on multiple daily injections, and appraise the evidence base for newer-generation insulin analogues, such as insulin degludec, glargine U300, faster-acting insulin aspart and BioChaperone lispro. We also highlight new insulins in development and unmet needs in people with Type 1 diabetes.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Clinical, PK/PD data, Review, Journal:  Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences. (Pubmed Central) -  May 26, 2021   
    Indeed, change from baseline in 1-h postprandial glucose increment is in favour of faster aspart versus IAsp when used as basal-bolus or CSII treatment in phase III trials in subjects with T1D or T2D. This review summarises the currently published results from clinical pharmacology trials with faster aspart and discusses the potential clinical benefits of faster aspart compared with previous rapid-acting insulin products.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    Phase classification, Metastases:  FACT: Fast Advanced Closed-Loop Therapy (clinicaltrials.gov) -  May 13, 2021   
    P=N/A,  N=33, Recruiting, 
    The simulation studies indicate that using Fiasp® in place of NovoLog® with the MiniMed 670G system will significantly improve the time spent in the healthy, euglycemic range and reduce exposure to hyperglycemia and hypoglycemia in most patients. Phase classification: P4 --> P=N/A
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion date, Trial primary completion date:  Comparison of FiAsp and Aspart During Postprandial Exercise in Adults With Type 1 Diabetes (clinicaltrials.gov) -  May 6, 2021   
    P4,  N=40, Recruiting, 
    Phase classification: P4 --> P=N/A Trial completion date: Feb 2021 --> May 2022 | Trial primary completion date: Feb 2021 --> Feb 2022
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    New P4 trial, Metastases:  FACT: Fast Advanced Closed-Loop Therapy (clinicaltrials.gov) -  Apr 20, 2021   
    P4,  N=33, Recruiting, 
  • ||||||||||  Symlin (pramlintide) / AstraZeneca, Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion:  Pramlintide and Fiasp Closed-Loop With a Simple Meal Announcement (clinicaltrials.gov) -  Apr 1, 2021   
    P=N/A,  N=8, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    [VIRTUAL] GAD-associated encephalitis in a 15-year-old boy with type I diabetes mellitus: a case report (Zoom Channel 4) -  Mar 21, 2021 - Abstract #DDG2021DDG_87;    
    The present case report supports the growing literature on autoimmune neurological diseases associated with high GAD antibody titers (1-3). Therefore, in the case of neurological symptoms in children and adolescents with type I DM, this association should be considered and, if necessary, appropriate immunodiagnostics performed.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion, Real-world evidence, Real-world:  Effect of Fiasp (clinicaltrials.gov) -  Feb 21, 2021   
    P=N/A,  N=244, Completed, 
    Therefore, in the case of neurological symptoms in children and adolescents with type I DM, this association should be considered and, if necessary, appropriate immunodiagnostics performed. Enrolling by invitation --> Completed
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Enrollment open:  An Indian Post Marketing Study of Mealtime Insulin, Fiasp (clinicaltrials.gov) -  Feb 17, 2021   
    P=N/A,  N=300, Enrolling by invitation, 
    In combination with insulin degludec, faster aspart provided effective overall glycemic control, superior PPG control, and a lower rate of severe or BG-confirmed hypoglycemia versus IAsp in adults with type 2 diabetes not optimally controlled with a basal-bolus regimen. Not yet recruiting --> Enrolling by invitation
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Enrollment open:  Fast-Acting Insulin Aspart and Insulin Pump Settings (clinicaltrials.gov) -  Feb 15, 2021   
    P4,  N=40, Recruiting, 
    Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion date, Trial primary completion date:  The Insulin-Only Bionic Pancreas Pivotal Trial (clinicaltrials.gov) -  Feb 9, 2021   
    P=N/A,  N=440, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Feb 2021 --> Dec 2021 | Trial primary completion date: Oct 2020 --> Aug 2021
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion:  real-FIASPISCI: Faster Aspart on Insulin-pump Treated T1DM Patients (clinicaltrials.gov) -  Jan 31, 2021   
    P=N/A,  N=48, Completed, 
    Trial completion date: Feb 2021 --> Dec 2021 | Trial primary completion date: Oct 2020 --> Aug 2021 Recruiting --> Completed
  • ||||||||||  Admelog (insulin lispro biosimilar) / Sanofi, Lyumjev (insulin lispro-aabc injection) / Eli Lilly
    Journal:  Lyumjev - a new insulin lispro for diabetes. (Pubmed Central) -  Jan 26, 2021   
    Recruiting --> Completed No abstract available
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    That's not fiasp (Twitter) -  Nov 14, 2020